Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's 0.97 not 0.097 per share
I just picked up 3M
0.1707 on the ask?????
Best post of the day. Thank you
Come and listen to my story about a man named Jed
A poor mountaineer, barely kept his family fed,
And then one day he was shootin at some food,
And up through the ground come a bubblin crude.
Oil that is, black gold, Texas Tea....$1 - $3.88
Shares usually trade at multiple of earnings. 20 to 30 times is the average. At 10x your calculations would give it a $4.80 share price
I just round off to 7000000 shares...just added 4 million...Thank you sellers
ENZC producing a Covid vaccine is a game changer
Great overview. Thank you Bonnie
Oil stocks are all up today. Should close at +0.03 in anticipation of news next week
0.25 coming
This could be bigger than anyone ever imagined. It will make the $3.88 price target look like chump change
Price is indicating that news may be imminent
With this price action...im getting FOMO on this one...only purchased 2M shares
In with 800000 shares because the Whale is here...
0.10 is doable...$1.00 is very possible with a partnership announcement.
We may hit 0.06 today. Getting noticed.
Big walls keep getting put up for MM's to buy cheaper shares. Hit the ask and let it run...
COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The agreements are with the Company's partners in IMBL formed with a group of successful Bulgarian businessmen.
As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV
leading to the planned clinical trials under the European Medicine Agency (the "EMA"). A commitment for funding of the cost of clinical trials under EMA guidelines and cost associated with the issuance of an EMA permit are part of the negotiated agreements. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company's belief is that issuance of the EMA permit for the ITV-1 compound should qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage Clinic Design to begin the clinical trials that is expected to be required under EMA standards. In addition, the Company is negotiating with an International known and respected European Contract Manufacturing organization ("CMO") to manufacture the required quantities of the ITV-1 Treatment to facilitate the clinical trials and permitting process under EMA guidelines.
The Company continues audits of the Company's current and prior year Financial Statements. An application for OTCQB is being prepared for submission upon issuance of the Audited Statements. The Company plans to complete the two-year audit as quickly as possible but will file the December 31, 2020 Annual Report Financial Statements pursuant to the OTC Markets Pink Basic Disclosure Guidelines. The Company plans the filing of the financial statements under the Basic Disclosure Guidelines for December 31, 2020, before the filing deadline of March 31, 2021.
CSO Harry Zhabilov stated, "As the Company progresses in its efforts to commercialize all the current and yet to be discovered opportunities of its patented treatments, the addition of IMBL and the benefits of obtaining an EMA permit has opened up new and exciting avenues for growth of our Company and the associated potential increase in value to its shareholders."
About Enzolytics, Inc.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About BioClonetics Immunotherapeutics, Inc.
BioClonetics Immunotherapeutics, Inc., a wholly owned subsidiary of Enzolytics, is a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the Coronavirus.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. ITV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of ITV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of ITV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.
IR Contact:
Enzolytics, Inc.
2000 North Central Expressway
Plano, TX 75074
Phone: (972) 292-9414 Fax: (972) 292-9414
and
Research Center
Enzolytics, Inc.
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843-4478
SOURCE: Enzolytics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/635741/Enzolytics-Finalizes-Documentation-with-International-Medical-Partners-Ltd-for-Clinical-Trials-and-Initial-Production-of-ITV-1-Company-Also-Provides-Update-on-Year-End-Reporting
?
Get your math right. The Canadian folks will see paper at 0.78...at $5.00...Canadians will be at $6.25...
Look at $EYES today. That's us soon...
The current price action has nothing to do with the ENZC...the OTC is just being manipulated for MMs to pick up cheaper shares for the next run. Don't be weak and sell as you will regret it. I sold 2M shares when the price dropped from 0.12 to 0.04...I still have over 2M and I will not sell till the earliest end of year. I learned my lesson by selling on fear. Don't let this happen to you as you will regret it all day...every day. Know what you own.
The float is only 220 million shares. Just bought up almost 10% of the float. Less than 10% of ENZC float which is trading at 0.50...Think of the huge potential here...$$$$$
After much DD jumped in with 2 Million shares...definitely chance of this hitting $1
Lesson 1: Remember, BASHERS NEVER Bash A BAD STOCK. Check the boards for stocks with no potential. They never have any Bashers. Bashers only go after stocks that are moving up or have excellent potential to do so. Bashers work to bring the price down to either increase their position at the expense of others or help a Short make their bones.
Considering the market is a bloodbath...we're holding up pretty well. If markets were up we would have been at 0.12 today. 40% discount if your buying
Buys are coming in...wouldn't be surprised to close over 0.10. Nothing has changed. The OTC market is getting scooped by stop losses for gains later in the week.
These are MM's trading among themselves to give the impression of a price drop so they can scare people into selling their shares cheap. If you can stay strong and not sell...the price will go up
0.35 by March 1st....minimum
This isn't the news we've been waiting for. More to come...groundbreaking
The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 187.94% during the next 3 months and, with a 90% probability hold a price between $0.18 and $0.50 at the end of this 3-month period.
Keep buying...squeeze the shorts and we'll beat 0.20 instantly
Don't sell. 0.35 coming within 2 to 3 weeks if not sooner